Breaking News Instant updates and real-time market news.

JPM

JPMorgan

$108.06

-3.59 (-3.22%)

, WFC

Wells Fargo

$51.42

-1.02 (-1.95%)

20:25
10/11/18
10/11
20:25
10/11/18
20:25

Notable companies reporting before tomorrow's open

Notable companies reporting before tomorrow's open, with earnings consensus, include JPMorgan (JPM), consensus $2.25... Wells Fargo (WFC), consensus $1.17... Citigroup (C), consensus $1.69... PNC Financial (PNC), consensus $2.72... First Republic Bank (FRC), consensus $1.21.

JPM

JPMorgan

$108.06

-3.59 (-3.22%)

WFC

Wells Fargo

$51.42

-1.02 (-1.95%)

C

Citi

$68.38

-1.57 (-2.24%)

PNC

PNC Financial

$131.62

-4.53 (-3.33%)

FRC

First Republic

$90.84

-2.23 (-2.40%)

  • 12

    Oct

  • 12

    Oct

  • 12

    Oct

  • 12

    Oct

  • 12

    Oct

  • 19

    Oct

  • 21

    Oct

  • 25

    Oct

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Jan

  • 16

    Jan

  • 26

    Feb

  • 12

    Apr

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 17

    Jul

  • 12

    Oct

  • 16

    Oct

JPM JPMorgan
$108.06

-3.59 (-3.22%)

08/22/18
SBSH
08/22/18
NO CHANGE
SBSH
JPMorgan mobile trading platform 'another salvo' on online brokers, says Citi
JPMorgan's (JPM) reported zero cost mobile trading service to be launched next week is "another salvo" in the war on broker dealers' fundamentals, Citi analyst William Katz tells investors in a research note. JPMorgan's move further underscores the commoditization risk to pricing across the retail broker dealer complex, particularly online brokers, the analyst adds. Further, he believes the new product adds an additional degree of difficulty to pricing a potential E-Trade (ETFC) acquisition or other retail broker deals. The analyst's work suggests negative 3% and negative 1% earnings risk to TD Ameritrade (AMTD) and Charles Schwab (SCHW), respectively. However, Katz believes much of the negativity is already priced into Ameritrade following yesterday's selloff. For Schwab, he believes continued pressure on Investor Services presents further downside risk in the stock from here.
08/22/18
DBAB
08/22/18
NO CHANGE
DBAB
JPMorgan mobile launch a catalyst for industry consolidation, says Deutsche
Deutsche Bank analyst Brian Bedell believes JPMorgan's (JPM) reported rollout of online trading to its 47M customers next week should be a catalyst for online broker industry consolidation. The analyst believes the news supports his TD Ameritrade (AMTD), E-Trade (ETFC) merger scenario thesis. He points out that his model already includes "substantial" trade price compression.
09/25/18
WOLF
09/25/18
INITIATION
Target $140
WOLF
Outperform
JPMorgan initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated JPMorgan with an Outperform and $140 price target.
10/03/18
BERN
10/03/18
NO CHANGE
BERN
Amazon to be accelerant of disruption coming for healthcare, says Bernstein
Bernstein analyst Lance Wilkes believes disruption is coming for healthcare and that Amazon (AMZN) will be an accelerant of this disruption. Further, the analyst sees a parallel with the fast changes in health insurance which took place in the 90's, when health insurance changed from 90% indemnity to 80% managed care within ten years. Wilkes thinks Amazon is developing a series of business strategies for entering healthcare market segments, namely directly entering online pharmacy, creating a disruptor in the employer healthcare space through its venture with Berkshire (BRK.A) and JPMorgan (JPM), and entering digital consumer healthcare spaces including using Alexa for consumer engagement and behavior modification.
WFC Wells Fargo
$51.42

-1.02 (-1.95%)

09/12/18
JPMS
09/12/18
NO CHANGE
JPMS
Underweight
Reported OCC rejection would be negative for Wells, says JPMorgan
According to Reuters, Office of the Comptroller of the Currency regulators have rejected Wells Fargo's plan to repay its auto customers who were pushed to buy unnecessary auto insurance, JPMorgan analyst Vivek Juneja tells investors in a research note. This rejection would be a negative for Wells as it may be required to spend more and take more time to satisfy regulators, the analyst writes. He also views the news negatively overall for the bank's ongoing regulatory issues. Juneja reiterates an Underweight rating on shares of Wells Fargo.
09/28/18
UBSW
09/28/18
NO CHANGE
Target $63
UBSW
Buy
Wells Fargo app download data suggests no momentum slowdown, says UBS
UBS analyst Saul Martinez reassessed Wells Fargo client engagement and employee sentiment and found that app download data was encouraging and showed no slowdown in momentum. Employee sentiment, however, showed a material weakening. The analyst said meaningful improvements in earnings power and profitability require revenue to stabilize and the recent share weakness may be due to concerns that business momentum and top line growth will continue to lag. Martinez maintained his Buy rating and $63 price target on Wells Fargo shares.
09/25/18
WOLF
09/25/18
INITIATION
Target $71
WOLF
Outperform
Wells Fargo initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Wells Fargo with an Outperform and $71 price target.
09/17/18
EDJN
09/17/18
UPGRADE
EDJN
Buy
Wells Fargo upgraded to Buy from Hold at Edward Jones (Friday)
C Citi
$68.38

-1.57 (-2.24%)

07/27/18
RHCO
07/27/18
NO CHANGE
Target $240
RHCO
Buy
MasterCard price target raised to $240 from $215 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on MasterCard to $240 and kept his Buy rating, saying the company is demonstrating expansion of global market share while posting a 14% Q2 volume growth. The analyst adds that while MasterCard has a higher valuation than PayPal (PYPL) and Visa (V) - a 10% relative EBITDA premium - it is justified and may even be too narrow given its superior growth sustainability and margin upside.
09/19/18
OPCO
09/19/18
NO CHANGE
OPCO
Outperform
U.S. banks 'in very good shape,' says Oppenheimer, favorites include BofA, Citi
Oppenheimer analyst Chris Kotowski tells investors in a research note that the U.S. banking group is on solid footing with balance sheets less risky than at any time over the last 33 years the firm covered the group and says his favorite bank stocks are Outperform-rated Bank of America (BAC), Citi (C), CIT (CIT) and Goldman Sachs (GS). However, Kotowski notes that banks are trading at an average relative P/E of just ~66% relative to the S&P 500 and returning to a historical avg valuation of 73%-80% range would imply over a thousand basis points of outperformance by the group. In his view, the U.S. banks are, on the whole, in "very good" shape.
09/25/18
WOLF
09/25/18
INITIATION
Target $91
WOLF
Outperform
Citi initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Citi with an Outperform and $91 price target.
08/28/18
WELS
08/28/18
NO CHANGE
Target $100
WELS
Outperform
Citi to benefit from potential U.S.-Mexico trade deal, says Wells Fargo
Wells Fargo analyst Mike Mayo believes Citi could gain more than other large U.S. banks from a U.S.-Mexico trade deal given its ownership of the second largest bank in Mexico, Citibanamex. In his view, Citi's stock had been hurt on perceptions of the U.S. relationship with Mexico. At a minimum, any new trade deal could reflect the absence of a negative and, on the upside, new potential growth opportunities, he contends. Mayo reiterates an Outperform rating and $100 price target on the shares.
PNC PNC Financial
$131.62

-4.53 (-3.33%)

06/14/18
RBCM
06/14/18
NO CHANGE
Target $170
RBCM
Top Pick
PNC Financial EPS view cut at RBC Capital on reduced mortgage banking outlook
RBC Capital analyst Gerard Cassidy lowered his PNC Financial FY18 EPS view to $10.51 from $10.60 and FY19 view to $11.32 from $11.46 after the recent commentary by the management that its Q2 mortgage banking revenues are tracking to be 12% lower than in Q1. The analyst keeps his Top Pick rating and $170 price target however, saying the bank is well positioned for higher interest rates that would expand its net interest income and also has a high 42% of the total component for its non-interest income. Cassidy adds that the regulatory environment benefits could also exceed his expectations.
07/20/18
OPCO
07/20/18
NO CHANGE
OPCO
Perform
Wells Fargo's next few earnings reports likely to be 'choppy,' says Oppenheimer
Oppenheimer analyst Chris Kotowski maintained a Perform rating on Wells Fargo (WFC) after recent meetings with CFO John Shrewsberry. In a research note to investors, Kotowski says there was nothing that shakes his view that the next few quarterly earnings reports are likely to still be "choppy," and notes that Shewsberry "readily acknowledged" that there was much work to be done to get the consent order lifted. At the same time, the analyst contends that shares are not trading at much of a discount versus other high performing banks like JPMorgan (JPM) and PNC (PNC) and says he favors companies that have lower but rising ROTCEs that are trading near TBV, especially Citi (C), CIT (CIT) and Goldman (GS).
04/16/18
BARD
04/16/18
NO CHANGE
Target $153
BARD
Outperform
PNC Financial weakness overdone, says Baird
Baird analyst David George said PNC Financial posted a clean quarter and he would be a buyer of the shares on the post-earnings weakness. The analyst noted fees were down seasonally, but the bank posted good year-over-year growth. George maintained his Outperform rating and $153 price target on PNC Financial shares.
05/30/18
BARD
05/30/18
NO CHANGE
Target $153
BARD
Outperform
PNC Financial added as Fresh Pick at Baird
Baird analyst David George said the weakness in PNC Financial is a buying opportunity and said it screens as one of the better values among regional banks. The analyst likes the bank's competitive positioning, solid intermediate-term outlook, and its current valuation. George reiterated his Outperform rating and $153 price target on PNC Financial shares.
FRC First Republic
$90.84

-2.23 (-2.40%)

06/26/18
WELS
06/26/18
NO CHANGE
Target $100
WELS
Market Perform
First Republic price target raised to $100 from $95 at Wells Fargo
Wells Fargo analyst Jared Shaw raised his price target for First Republic to $100 from $95 heading into Q2 as he believes the banking industry continues to benefit from a level of structural tailwinds he has not seen in over a decade. The analyst reiterates a Market Perform rating on the shares.
07/16/18
BMOC
07/16/18
NO CHANGE
Target $102
BMOC
Market Perform
First Republic price target raised to $102 from $96 at BMO Capital
BMO Capital analyst Lana Chan raised her price target on First Republic to $102 after its Q2 earnings beat that was driven "solely by a lower tax rate". Chan notes that while the company continues to generate "impressive" growth in lending, deposits, and assets under management, the positive developments are already reflected in its "5-multiple premium to smid-cap peers". The analyst keeps her Market Perform rating on First Republic.
09/13/18
RBCM
09/13/18
NO CHANGE
Target $102
RBCM
Sector Perform
First Republic price target raised to $102 from $97 at RBC Capital
RBC Capital analyst Jon Arfstrom raised his price target on First Republic to $102 as part of his model "fine tuning" following the bank's common equity offering. The analyst says the capital raise was "consistent" with its continued growth strategy and outlook, adding the management has been "disciplined and conservative" with its capital strategy. Arfstrom adds that he still views First Republic as a "very high quality core holding for long term investors" but keeps his Sector Perform rating, saying the stance reflects the bank's valuation relative to its peers.
06/18/18
SBSH
06/18/18
INITIATION
Target $120
SBSH
Buy
First Republic initiated with a Buy at Citi
Citi analyst Arren Cyganovich started First Republic Bank with a Buy rating and $120 price target.

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:38
10/19/18
10/19
17:38
10/19/18
17:38
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

TEUM

Pareteum

$2.47

-0.07 (-2.76%)

17:36
10/19/18
10/19
17:36
10/19/18
17:36
Syndicate
Breaking Syndicate news story on Pareteum »

Pareteum files $150M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 15

    Nov

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

, LMT

Lockheed Martin

$328.22

0.21 (0.06%)

17:33
10/19/18
10/19
17:33
10/19/18
17:33
Periodicals
Trump to meet CEOs of Boeing, Lockheed Martin, General Dynamics, Reuters reports »

President Donald Trump…

NOC

Northrop Grumman

$307.77

-0.445 (-0.14%)

LMT

Lockheed Martin

$328.22

0.21 (0.06%)

BA

Boeing

$356.28

-3 (-0.84%)

GD

General Dynamics

$190.43

-0.76 (-0.40%)

BAESY

BAE Systems

$0.00

(0.00%)

HON

Honeywell

$153.49

-1.73 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 30

    Oct

ISR

IsoRay

$0.50

0.0191 (3.98%)

17:25
10/19/18
10/19
17:25
10/19/18
17:25
Syndicate
Breaking Syndicate news story on IsoRay »

IsoRay files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHS

Neuberger Berman High Yield Strategies Fd

$10.55

-0.015 (-0.14%)

17:06
10/19/18
10/19
17:06
10/19/18
17:06
Hot Stocks
Breaking Hot Stocks news story on Neuberger Berman High Yield Strategies Fd »

Saba Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIOC

Biocept

$2.27

-0.04 (-1.73%)

17:04
10/19/18
10/19
17:04
10/19/18
17:04
Syndicate
Breaking Syndicate news story on Biocept »

Biocept files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZO

AutoZone

$726.10

-4.09 (-0.56%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Hot Stocks
AutoZone founder Hyde will not stand for board re-election »

AutoZone announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SACH

Sachem Capital

$4.33

0.02 (0.46%)

17:03
10/19/18
10/19
17:03
10/19/18
17:03
Syndicate
Breaking Syndicate news story on Sachem Capital »

Sachem Capital files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

16:53
10/19/18
10/19
16:53
10/19/18
16:53
Conference/Events
Mirati Therapeutics to hold a conference call »

Dr. Charles Baum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

SPNE

SeaSpine

$16.58

-0.54 (-3.15%)

16:47
10/19/18
10/19
16:47
10/19/18
16:47
Hot Stocks
Breaking Hot Stocks news story on SeaSpine »

First Light Asset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$8.76

-0.04 (-0.45%)

16:46
10/19/18
10/19
16:46
10/19/18
16:46
Conference/Events
Epizyme to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

16:40
10/19/18
10/19
16:40
10/19/18
16:40
General news
Breaking General news story on MSCI Italy Index, SPDR S&P 500 ETF Trust, S&P 500 »

Moody's cuts Italy…

EWI

MSCI Italy Index

$25.52

0.38 (1.51%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASTC

Astrotech

$2.93

-0.02 (-0.68%)

16:39
10/19/18
10/19
16:39
10/19/18
16:39
Hot Stocks
Breaking Hot Stocks news story on Astrotech »

Winn Interests reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTMX

CytomX Therapeutics

$15.43

-1.075 (-6.52%)

16:38
10/19/18
10/19
16:38
10/19/18
16:38
Conference/Events
CytomX Therapeutics to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

ICLK

iClick Interactive Asia

$3.41

(0.00%)

16:36
10/19/18
10/19
16:36
10/19/18
16:36
Hot Stocks
Breaking Hot Stocks news story on iClick Interactive Asia »

LIM Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.